CHF Solutions Announces Launch of Aquapheresis Therapy Using Aquadex FlexFlow® System at the Baylor Scott & White Health Sys...
January 22 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS) today announced that Texas-based
health system, Baylor Scott & White Health has initiated
offering aquapheresis therapy using the company’s Aquadex FlexFlow®
system at its Baylor Scott & White Medical Center in Temple,
Texas.
“Fluid overload continues to be an issue to be managed in the
acute and chronic care settings, and CHF Solutions’ Aquadex
FlexFlow System has continually proven to be a viable and
easy-to-maintain solution for managing these patients and improving
their quality of life while reducing the cost of care,” said John
Erb, CEO of CHF Solutions. “We are proud to provide products to
Baylor Scott & White Medical Center -Temple and look forward to
assisting its clinicians in the care of their fluid overloaded
patients.”
Baylor Scott & White Health is the largest not-for-profit
health care system in Texas and one of the largest in the United
States. With a commitment to and a track record of innovation,
collaboration, integrity and compassion for the patient, Baylor
Scott & White Health stands to be one of the nation’s exemplary
health care organizations. Its mission is to serve all people by
providing personalized health and wellness through exemplary care,
education and research as a Christian ministry of healing.
About CHF SolutionsCHF
Solutions, Inc. (Nasdaq: CHFS) is a medical device company
dedicated to changing the lives of patients suffering from fluid
overload through science, collaboration, and innovation. The
company is focused on developing, manufacturing, and
commercializing the Aquadex FlexFlow system for ultrafiltration
therapy. CHF Solutions is a Delaware corporation headquartered in
Minneapolis, Minnesota with wholly owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
About Aquadex FlexFlow® System The Aquadex
FlexFlow system is a clinically proven therapy that provides a
safe, effective, and predictable method of removing excess fluid
from patients suffering from fluid overload. The Aquadex FlexFlow
system is indicated for temporary (up to eight hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy, and for extended (longer than 8 hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and require hospitalization. The company
has submitted an application to the FDA requesting for 510(k)
clearance of the Aquadex FlexFlow system to include pediatric
patients who weigh 20kg or more. All treatments must be
administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies.
Forward-Looking StatementsCertain statements in
this release are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including
without limitation, statements regarding the clinical performance
of the Aquadex FlexFlow system and the company’s plans to assist
clinicians in the care of patients. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our ability to execute on
our commercialization strategy, the possibility that we may be
unable to raise sufficient funds necessary for our anticipated
operations, our post-market clinical data collection activities,
benefits of our products to patients, our expectations with respect
to product development and commercialization efforts, our ability
to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property
protection, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak
only as of the date when made. CHF Solutions does not assume any
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024